Replies to post #754140 on NorthWest Biotherapeutics Inc (NWBO)

[theorysuit]

You cant have a logical argument with him. He is a paid pumper who excels at writing paragraphs of nothing.

What is the cost and you get verbal diarrhea.

[Investor082]

The dude is a well known know it all pumper, yet does not expect shareholders to be making money on their NWBO investment! ;)

Either way, none of this matters. The revenue from the UK will be so tiny in 2025 and 2026. Less than $15M annually (without reimbursement support). More importantly, it’s clear there will be no non dilutive funds from big pharma. Which means endless dilution in 2025 & 2026. Another thing that is quite likely is a lawsuit in Q4, 2025. Lies and dangling of carrots catches up at around the 5 year anniversary of data lock.

UK approval may present the best opportunity to take whatever money off the table one can over the next couple of years while LP continues to dilute shareholders to oblivion. Watch out for the next set of carrots - Flaskworks, fast combo trial(s), etc. Unfortunately, they don't have money to do any of this aggressively and in a reasonable time frame. Yet expect dilution to increase massively. LP will beg shareholders to raise authorized share count at the ASM this year. Wait and watch!